Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics

Aridis Pharmaceuticals Inc. (ARDS): $0.07

0.00 (-2.45%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

ARDS Price/Volume Stats

Current price $0.07 52-week high $0.54
Prev. close $0.07 52-week low $0.05
Day low $0.07 Volume 37,000
Day high $0.07 Avg. volume 101,239
50-day MA $0.07 Dividend yield N/A
200-day MA $0.11 Market Cap 3.44M

ARDS Stock Price Chart Interactive Chart >


Aridis Pharmaceuticals Inc. (ARDS) Company Bio


Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.


ARDS Latest News Stream


Event/Time News Detail
Loading, please wait...

ARDS Latest Social Stream


Loading social stream, please wait...

View Full ARDS Social Stream

Latest ARDS News From Around the Web

Below are the latest news stories about ARIDIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET).

Yahoo | June 30, 2023

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Yahoo | June 21, 2023

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacteri

Yahoo | June 20, 2023

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023. First Quarter & Subsequent Highlights Met primary safety and secondary pharmacokinetics endpoints in AR-501 Phase 2a study in cystic fibrosis (CF). CF patients achiev

Yahoo | June 8, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!

William White on InvestorPlace | June 1, 2023

Read More 'ARDS' Stories Here

ARDS Price Returns

1-mo -12.50%
3-mo N/A
6-mo 22.81%
1-year -68.18%
3-year -98.76%
5-year -99.29%
YTD -0.14%
2023 -94.06%
2022 -49.36%
2021 -61.61%
2020 36.40%
2019 -59.87%

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!